Quick Answer
IGC Pharma, Inc. reported Total Revenue of $1.27 million for fiscal year 2025.
IGC Pharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.27M -5.5% |
$1.34M +47.6% |
$911.0K +129.5% |
$397.0K -55.8% |
$898.0K -77.9% |
$4.07M -20.4% |
| Net Income | -$7.12M +45.2% |
-$13.00M -13.0% |
-$11.51M +23.4% |
-$15.02M -70.4% |
-$8.81M -20.5% |
-$7.32M -78.5% |
| Diluted EPS | -$0.09 +59.1% |
-$0.22 | — | — | — | — |
| Total Assets | $8.75M -11.7% |
$9.90M -42.4% |
$17.18M -36.0% |
$26.83M -25.2% |
$35.87M +23.7% |
$28.98M -15.9% |
| Cash and Equivalents | $405.0K -66.2% |
$1.20M -62.5% |
$3.20M -69.4% |
$10.46M -28.1% |
$14.55M +100.4% |
$7.26M -71.7% |
| Long-Term Debt | $134.0K -2.2% |
$137.0K -2.8% |
$141.0K -2.1% |
$144.0K -47.8% |
$276.0K | $0.00 |
| Stockholders Equity | $6.33M -13.5% |
$7.32M -50.9% |
$14.91M -37.6% |
$23.89M -27.2% |
$32.80M +23.6% |
$26.54M -21.0% |
| R&D Expense | $3.65M -3.1% |
$3.77M +9.0% |
$3.46M +48.5% |
$2.33M +150.8% |
$929.0K -8.1% |
$1.01M -19.5% |
| Operating Income | -$7.45M +24.0% |
-$9.80M +15.3% |
-$11.57M +25.0% |
-$15.43M -76.8% |
-$8.72M -27.1% |
-$6.86M -47.8% |
| Gross Profit | $619.0K -15.6% |
$733.0K +65.8% |
$442.0K +127.8% |
$194.0K +71.7% |
$113.0K -1.7% |
$115.0K -12.9% |
| Shares Outstanding | 80.88M +21.3% |
66.69M +25.6% |
53.08M +4.0% |
51.05M +6.7% |
47.83M +21.6% |
39.32M -0.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $191.0K | -53.6% | -41.8% |
| Net Income | September 30, 2025 | -$1.82M | -6.1% | -13.9% |
| Diluted EPS | September 30, 2025 | -$0.02 | +0.0% | +0.0% |
| Total Assets | September 30, 2025 | $9.74M | -6.0% | +22.7% |
| Cash and Equivalents | September 30, 2025 | $1.10M | -28.5% | +143.4% |
| Long-Term Debt | September 30, 2025 | $132.0K | -2.2% | -0.8% |
| Stockholders Equity | September 30, 2025 | $8.09M | +9.7% | +33.1% |
| R&D Expense | September 30, 2025 | $1.59M | +73.2% | +86.6% |
| Operating Income | September 30, 2025 | -$2.90M | -64.7% | -52.2% |
| Gross Profit | September 30, 2025 | $99.0K | -50.0% | -35.7% |
| Shares Outstanding | September 30, 2025 | 91.96M | +20.0% | +9.3% |
- IGC Pharma, Inc. reported Total Revenue of $1.27 million for fiscal year 2025.
- IGC Pharma, Inc. showed a decrease of -5.5% in Total Revenue compared to the prior fiscal year.
- IGC Pharma, Inc. reported Net Income of -$7.12 million for fiscal year 2025.
- IGC Pharma, Inc. showed an increase of +45.2% in Net Income compared to the prior fiscal year.
- IGC Pharma, Inc. reported Diluted EPS of $0.09 per share (loss) for fiscal year 2025.
- IGC Pharma, Inc. showed an increase of +59.1% in Diluted EPS compared to the prior fiscal year.
- IGC Pharma, Inc. reported Total Assets of $8.75 million for fiscal year 2025.
- IGC Pharma, Inc. showed a decrease of -11.7% in Total Assets compared to the prior fiscal year.
- IGC Pharma, Inc. reported Cash and Equivalents of $405.0 thousand for fiscal year 2025.
- IGC Pharma, Inc. showed a decrease of -66.2% in Cash and Equivalents compared to the prior fiscal year.
- IGC Pharma, Inc. reported Long-Term Debt of $134.0 thousand for fiscal year 2025.
- IGC Pharma, Inc. showed a decrease of -2.2% in Long-Term Debt compared to the prior fiscal year.
- IGC Pharma, Inc. reported Stockholders Equity of $6.33 million for fiscal year 2025.
- IGC Pharma, Inc. showed a decrease of -13.5% in Stockholders Equity compared to the prior fiscal year.
- IGC Pharma, Inc. reported R&D Expense of $3.65 million for fiscal year 2025.
- IGC Pharma, Inc. showed a decrease of -3.1% in R&D Expense compared to the prior fiscal year.
- IGC Pharma, Inc. reported Operating Income of -$7.45 million for fiscal year 2025.
- IGC Pharma, Inc. showed an increase of +24.0% in Operating Income compared to the prior fiscal year.
- IGC Pharma, Inc. reported Gross Profit of $619.0 thousand for fiscal year 2025.
- IGC Pharma, Inc. showed a decrease of -15.6% in Gross Profit compared to the prior fiscal year.
- IGC Pharma, Inc. reported Shares Outstanding of 80.88 million shares for fiscal year 2025.
- IGC Pharma, Inc. showed an increase of +21.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: